Reasons for trisomy 13 or 18 births despite the availability of prenatal diagnosis and pregnancy termination

Early Human Development

Volumn 73, Issue 1-2, 2003, Pages 53-60

  Gessner, Bradford D ^a  

^a Alaska Division of Public Health   (United States)

Author keywords

Pregnancy termination; Prenatal diagnosis; Trisomy 13 or 18

Indexed keywords

ADOLESCENT; ADULT; AMNIOCENTESIS; ARTICLE; BIRTH RATE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FETUS ECHOGRAPHY; FETUS MORTALITY; GESTATIONAL AGE; HUMAN; MATERNAL CARE; MATERNAL MORTALITY; OUTCOMES RESEARCH; PERINATAL PERIOD; PREGNANCY TERMINATION; PRENATAL CARE; PRENATAL DIAGNOSIS; PRENATAL PERIOD; RISK ASSESSMENT; RISK FACTOR; TRISOMY 13; TRISOMY 18; UNITED STATES;

EID: 0042427777     PISSN: 03783782     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-3782(03)00072-0     Document Type: Article

References (17)

1. Hogge W.A., Fraer L., Melegari T. Maternal serum screening for fetal trisomy 18: benefits of patient-specific risk protocol. Am. J. Obstet. Gynecol. 185:2001 (Aug.);289-293.
2. Benn P.A., Leo M.V., Rodis J.F., Beazoglou T., Collins R., Horne D. Maternal serum screening for fetal trisomy 18: a comparison of fixed cutoff and patient-specific risk protocols. Obstet. Gynecol. 93:1999;707-711.
3. Schwarzler P., Carvalho J.S., Senat M.V., Masroor T., Campbell S., Ville Y. Screening for fetal aneuploidies and fetal cardiac abnormalities by nuchal translucency thickness measurement at 10-14 weeks of gestation as part of routine antenatal care in an unselected population. Br. J. Obstet. Gynaecol. 106:1999;1029-1034.
4. Wayda K., Kereszturi A., Orvos H., Horvath E., Pal A., Kovacs L.et al. Four years experience of first-trimester nuchal translucency screening for fetal aneuploidies with increasing regional availability. Acta Obstet. Gynecol. Scand. 80:2001;1104-1109.
5. Souter V.L., Nyberg D.A. Sonographic screening for fetal aneuploidy: first trimester. J. Ultrasound Med. 20:2001;775-790.
6. Whitlow B.J., Chatzipapas I.K., Lazanakis M.L., Kadir R.A., Economides D.L. The value of sonography in early pregnancy for the detection of fetal abnormalities in an unselected population. Br. J. Obstet. Gynaecol. 106:1999;929-936.
7. Shipp T.D., Benacerraf B.R. Second trimester ultrasound screening for chromosomal abnormalities. Prenat. Diagn. 22:2002;296-307.
8. Nyberg D.A., Souter V.L. Sonographic markers of fetal trisomies: second trimester. J. Ultrasound Med. 20:2001;655-674.
9. Benacerraf B.R., Nadel A., Bromley B. Identification of second-trimester fetuses with autosomal trisomy by use of a sonographic scoring index. Radiology. 193:1994;135-140.
10. Spencer K., Ong C., Skentou H., Liao A.W., Nicolaides H.K. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat. Diagn. 20:2000;411-416.
11. Tul N., Spencer K., Noble P., Chan C., Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free beta-hCG and PAPP-A at 10-14 weeks of gestation. Prenat. Diagn. 19:1999;1035-1042.
12. DeVore G.R., Romero R. Genetic sonography: a cost-effective method for evaluating women 35 years and older who decline genetic amniocentesis. J. Ultrasound Med. 21:2002;5-13.
13. Ralston S.J., Wertz D., Chelmow D., Craigo S.D., Bianchi D.W. Pregnancy outcomes after prenatal diagnosis of aneuploidy. Obstet. Gynecol. 97:2001;729-733.
14. Birth defects surveillance data from selected states, 1995-1999. Teratology. 66:2002;S129-S211.
15. Alaska Bureau of Vital Statistics. Annual reports for 1992 through 1999. Alaska Department of Health and Social Services, Division of Public Health.
16. DeVore G.R. The genetic sonogram: its use in the detection of chromosomal abnormalities in fetuses of women of advanced maternal age. Prenat. Diagn. 21:2001;40-45.
17. Smith-Bindman R., Hosmer W., Feldstein V.A., Deeks J.J., Goldberg J.D. Second-trimester ultrasound to detect fetuses with down syndrome: a meta-analysis. JAMA. 285:2001;1044-1055.